Targacept, a biopharmaceutical company developing a new class of drugs for the treatment of nervous system disorders, filed to go public on Friday. The company is currently marketing antihypertension agent Inversine and has four additional compounds in Phase I and II clinical trials. Morgan Stanley is the lead manager for the deal and will be assisted by Deutsche Bank Securities, CIBC World Markets and Pacific Growth Equities.
